Map
At IMMUNOLOGY 2024, research results about GAIA-102 were presented
Fukuoka, JAPAN – At IMMUNOLOGY 2024, held in Chicago, Illinois, USA, students at the Department of Innovative Biomedicine for Drug Discovery at Graduate School of Pharmaceutical Sciences, Kyushu University (Principal research scientist Professor Yoshi Yonemitsu), presented research results about GAIA-102.
Summary of presentations:
Presentation 1
Title: Impact of monocytes on the proliferation of highly activated NK-like cells (GAIA-102)
Poster Board Number: B629
Abstract ID: 6271
Presentation Author: Shuyue Yuan
Date: May 4
Presentation Time: 11:30 AM to 12:45 PM (Central Time)
Room: Exhibit Hall F1
https://aai.secure-platform.com/site/solicitations/102001/sessiongallery/94309/application/6271
Presentation 2
Title: GAIA-102 cells, an off-the-shelf and highly activated NK-like cell product, elicit endogenous immune cell responses in solid tumor model
Poster Board Number: B958
Abstract ID: 6270
Presentation Author: Situo Zheng
Date: May 6
Presentation Time: 02:15 PM to 03:30 PM (Central Time)
Room: Exhibit Hall F1
https://aai.secure-platform.com/site/solicitations/102001/sessiongallery/94429/application/6270
About GAIA-102:
GAIA-102 is a unique NK-like cell with high cytotoxic activity for various intractable solid tumors. Clinical trials are underway targeting non-small cell lung cancer (NSCLC), advanced Gastrointestinal Cancers (Gastric Cancer/Pancreatic Cancer) of Microsatellite Stable (MSS), and refractory/relapsed pediatric solid tumors, respectively.
